Ocrelizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ocrelizumab: From Progressive Multiple Sclerosis to HER2-Positive Breast Carcinoma
One-Sentence Summary
Ocrelizumab is an anti-CD20 antibody originally used to treat progressive multiple sclerosis. The TxGNN model predicts it may be effective for HER2-positive breast carcinoma, but there are currently 0 clinical trials and 0 publications supporting this specific indication. This is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Progressive multiple sclerosis |
| Predicted New Indication | HER2-positive breast carcinoma |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20-positive B cells. Its efficacy in multiple sclerosis is well documented (the OPERA I/II and ORATORIO trials).
No direct link to HER2-driven breast cancer biology was identified. A possible connection, such as B cells within the tumour microenvironment, is speculative, and B-cell depletion could be neutral or even unfavourable for anti-tumour immunity.
Several other breast-related predictions (progesterone-receptor positive, normal breast-like subtype, progesterone-receptor negative, luminal A or B) have nearly identical scores of about 0.998. This suggests the model is propagating a shared breast-cancer signal rather than indication-specific evidence. The lower-ranked predictions (benign tongue, hypopharynx and buccal mucosa neoplasms, cervical neuroblastoma, jugular foramen schwannoma) also lack any supporting evidence or plausible rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for HER2-positive breast carcinoma.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16871P | OCREVUS Concentrate for Solution for Infusion 300mg/10mL | Injection, solution, concentrate | Not listed in the compiled data |
Safety Considerations
- Drug Interactions: 100 interactions were identified. The main ones are moderate, involving corticosteroids (hydrocortisone, prednisolone, prednisone, dexamethasone, betamethasone, triamcinolone, budesonide), radiopharmaceuticals and radioimmunotherapies (iobenguane I-131, ibritumomab tiuxetan, tositumomab, samarium-153 lexidronam), and albendazole, pentamidine and levamisole. Minor interactions involve zinc salts (sulfate, acetate, gluconate, chloride).
- Other Considerations: Prolonged B-cell depletion carries a risk of secondary hypogammaglobulinaemia, as discussed in an AAAAI work group report.
For other safety information, including warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no clinical trials or literature for this indication. Mechanistically, there is no supported link between anti-CD20 B-cell depletion and HER2-positive breast cancer, and the near-identical scores across breast-cancer subtypes point to a non-specific model signal.
To proceed, the following is needed:
- Preclinical or mechanistic evidence for B-cell or CD20 involvement in HER2-positive breast cancer
- Detailed mechanism of action data
- Package insert warnings and contraindications from the HSA
- Evidence that benefit outweighs the immunosuppression risk in an oncology setting
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.